Skip to content

Sulfathiazole

DERMATOLOGICALS

Also known as: norsulfasol, norsulfazol, norsulfazole, sulfanilamidothiazole, sulfathiazol, sulphathiazole, thiazamide, thiozamide

OfmFDA approvedATC D06BA02ATC J01EB07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Sulfathiazole is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 1945. DrugCentral lists 4 molecular targets, including folP, lasR and EDNRA. Recorded indications include Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.

  • Approval status: ofm (first approved 1945 by the FDA).
  • Molecular targets: folP, lasR, EDNRA and Ednra (4 listed in DrugCentral).
  • Indications: Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.
  • ATC code: D06BA02 (Sulfonamides).
  • Molecular formula: C9H9N3O2S2; molecular weight 255.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Gardnerella Vaginalis Bacterial Vaginosis
  • Vulvovaginitis

Contraindications (7)

  • Anemia due to enzyme deficiency
  • Breastfeeding (mother)
  • Deficiency of glucose-6-phosphate dehydrogenase
  • Disease of blood AND/OR blood-forming organ
  • Disease of liver
  • Kidney disease
  • Porphyria

Mechanism & targets

Molecular targets (4)

TargetGeneActionActivity
Dihydropteroate synthasefolPinhibitorIC50 5.60
Transcriptional activator protein LasRlasRunknownIC50 5.05
Endothelin-1 receptorEDNRAunknownIC50 4.16
Endothelin-1 receptorEdnraunknownIC50 4.16

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1945-09-12FDA—ORTHO MCNEIL PHARM

ATC classification

ATC codeTherapeutic hierarchy
D06BA02DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Sulfonamides
J01EB07ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › SULFONAMIDES AND TRIMETHOPRIM › Short-acting sulfonamides

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Subcutaneous drug absorption impaired372.4
General symptom326.7
Pustular psoriasis324.0
Rash vesicular321.7
Breast cancer stage II313.2
Back disorder273.3
Adjustment disorder with depressed mood263.4
Dislocation of vertebra262.0
Myositis261.8
Folliculitis239.7
Wound infection236.8
Joint range of motion decreased229.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sulfathiazole is on its molecule page.

Molecular formulaC9H9N3O2S2
Molecular weight255.31 g/mol
CAS number72-14-0
InChIKeyJNMRHUJNCSQMMB-UHFFFAOYSA-N
PubChem CID5340
NC1=CC=C(C=C1)S(=O)(=O)NC1=NC=CS1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulfathiazole used for?

DrugCentral lists the following indications for Sulfathiazole: Gardnerella Vaginalis Bacterial Vaginosis and Vulvovaginitis.

How does Sulfathiazole work?

Its molecular targets in DrugCentral include folP (inhibitor), lasR, EDNRA and Ednra.

When was Sulfathiazole first approved?

Sulfathiazole was first approved by the FDA in 1945.

What is the chemical formula of Sulfathiazole?

Sulfathiazole has the molecular formula C9H9N3O2S2 and a molecular weight of 255.31 g/mol.

Browse: all drugs starting with S · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1945-09-12
AgencyFDA
Targets4
Indications2
FormulaC9H9N3O2S2
DrugCentral ID2527
Interactive profile